Loading
A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Yale University, not yet recruiting.
Sac-TMT for Active TNBC Brain Metastases is a phase 2, interventional study registered as NCT07458113 by Yale University, with a registry enrolment figure of 20 participants, started 2026-08 and due to reach its primary completion in 2028-08. Interventions recorded: Sacituzumab tirumotecan. Conditions listed: Metastatic Triple Negative Breast Cancers. Triple-negative eligibility wording from the registry: "Histologically and/or cytologically confirmed metastatic triple-negative breast cancer defined by estrogen receptor (ER) expression \<10%, progesterone receptor expression \<10% and HER2-negative status, defined by 0, 1+ or 2+ FISH negative by immunohistochemistry (IHC) by standard pathology". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Sacituzumab tirumotecan, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.